🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
BIV
$BIVI
🔒 US EquitiesBioVie Inc.
AVG HISTORICAL GAP
-2.13%
MAX GAP RECORD
-9.44%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $BIVI
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$BIVI
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Aug 24, 2026 Earnings Release 2026-08-24 (AFTER CLOSE) |
-6.54%
|
| Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE) |
-1.28%
|
| Aug 14, 2025 Earnings Release 2025-08-14 (AFTER CLOSE) |
+3.01%
|
| May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE) |
-1.74%
|
| Feb 11, 2025 Earnings Release 2025-02-11 (AFTER CLOSE) |
-9.44%
|
| May 14, 2024 Earnings Release 2024-05-14 (AFTER CLOSE) |
+0.60%
|
| Feb 13, 2024 Earnings Release 2024-02-13 (BEFORE OPEN) |
+0.00%
|
| Nov 08, 2023 Earnings Release 2023-11-08 (AFTER CLOSE) |
-6.10%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
3.2%
Bullish Gaps (2)
Bearish Gaps (5)
Neutral / Flat (3)
📖 Intelligence Summary
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗